• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis.

作者信息

Ungar Benjamin, Lavin Leore, Golant Alexandra K, Gontzes Alyssa, David Eden, Estrada Yeriel D, Singer Giselle K, Pavel Ana B, Guttman-Yassky Emma

机构信息

Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York.

Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Biomedical Engineering, The University of Mississippi, University, Mississippi.

出版信息

Ann Allergy Asthma Immunol. 2022 Jun;128(6):734-736. doi: 10.1016/j.anai.2022.03.019. Epub 2022 Mar 26.

DOI:10.1016/j.anai.2022.03.019
PMID:35346880
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8956356/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e33/8956356/856f999c8149/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e33/8956356/856f999c8149/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e33/8956356/856f999c8149/gr1_lrg.jpg

相似文献

1
The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis.度普利尤单抗治疗对特应性皮炎患者严重急性呼吸综合征冠状病毒2-冠状病毒病2019抗体反应的影响。
Ann Allergy Asthma Immunol. 2022 Jun;128(6):734-736. doi: 10.1016/j.anai.2022.03.019. Epub 2022 Mar 26.
2
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.度普利尤单抗治疗中重度特应性皮炎患者的 COVID-19 症状减轻。
J Allergy Clin Immunol Pract. 2022 Jan;10(1):134-142. doi: 10.1016/j.jaip.2021.10.050. Epub 2021 Nov 1.
3
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.青少年中重度特应性皮炎患者接受度普利尤单抗治疗的多中心意大利真实世界经验。
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1292-1299. doi: 10.1111/jdv.18141. Epub 2022 Apr 22.
4
Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study.患有特应性皮炎并接受度普利尤单抗治疗的患者罹患 COVID-19 及其并发症的风险：一项基于人群的队列研究。
Immunol Res. 2022 Feb;70(1):106-113. doi: 10.1007/s12026-021-09234-z. Epub 2021 Oct 13.
5
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.在新冠疫情期间使用度普利尤单抗治疗重度特应性皮炎成年患者的管理：一项单中心真实世界经验
Dermatol Ther. 2020 Jul;33(4):e13765. doi: 10.1111/dth.13765. Epub 2020 Jun 30.
6
The impact of dupilumab treatment on SARS-CoV-2 T cell responses in atopic dermatitis patients.度普利尤单抗治疗对特应性皮炎患者严重急性呼吸综合征冠状病毒2（SARS-CoV-2）T细胞反应的影响。
Allergy. 2023 Feb;78(2):571-574. doi: 10.1111/all.15540. Epub 2022 Oct 17.
7
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.度普利尤单抗治疗青少年中重度特应性皮炎的临床意义：一项随机临床试验的事后分析。
Am J Clin Dermatol. 2020 Feb;21(1):119-131. doi: 10.1007/s40257-019-00478-y.
8
COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis.新冠病毒不影响中度至重度特应性皮炎患者停用度普利尤单抗后的复发时间。
Dermatitis. 2024 Sep-Oct;35(5):523-524. doi: 10.1089/derm.2023.0304. Epub 2023 Dec 29.
9
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.青少年特应性皮炎或哮喘患者接受度普利尤单抗临床试验中的结膜炎。
Am J Clin Dermatol. 2021 Jan;22(1):101-115. doi: 10.1007/s40257-020-00577-1.
10
Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease.单克隆抗体联合治疗：度普利尤单抗和优特克单抗用于治疗重度特应性皮炎和克罗恩病。
Australas J Dermatol. 2024 Feb;65(1):63-66. doi: 10.1111/ajd.14185. Epub 2023 Nov 6.

引用本文的文献

1
A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology.接受度普利尤单抗治疗的患者使用疫苗的系统评价和专家 Delphi 共识推荐：美国过敏、哮喘和免疫学学会的立场文件。
Ann Allergy Asthma Immunol. 2024 Sep;133(3):286-294. doi: 10.1016/j.anai.2024.05.014. Epub 2024 Jun 5.
2
Ally, adversary, or arbitrator? The context-dependent role of eosinophils in vaccination for respiratory viruses and subsequent breakthrough infections.盟友、对手还是仲裁者？嗜酸性粒细胞在呼吸道病毒疫苗接种及其随后突破性感染中的上下文相关作用。
J Leukoc Biol. 2024 Jul 25;116(2):224-243. doi: 10.1093/jleuko/qiae010.
3
A novel protocol for de-isolating moderately and severely immunocompromised COVID-19 patients.
一种用于解除中度和重度免疫功能低下的新冠肺炎患者隔离的新方案。
Glob Health Med. 2023 Dec 31;5(6):366-371. doi: 10.35772/ghm.2023.01053.
4
Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review.2019年冠状病毒病大流行对特应性皮炎和食物过敏的成人及儿童的影响：系统评价
J Allergy Clin Immunol Glob. 2023 Oct 18;3(1):100181. doi: 10.1016/j.jacig.2023.100181. eCollection 2024 Feb.
5
Recent developments in the immunopathology of COVID-19.COVID-19 免疫病理学的最新进展。
Allergy. 2023 Feb;78(2):369-388. doi: 10.1111/all.15593. Epub 2022 Dec 5.
6
Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis.度普利尤单抗治疗中重度哮喘患者的疗效与安全性：一项系统评价与荟萃分析
Front Pharmacol. 2022 Oct 3;13:992731. doi: 10.3389/fphar.2022.992731. eCollection 2022.
7
Management of patients with allergic diseases in the era of COVID-19.2019冠状病毒病时代过敏性疾病患者的管理
Clin Exp Pediatr. 2022 Nov;65(11):529-535. doi: 10.3345/cep.2022.00759. Epub 2022 Sep 23.
8
Allergen Immunotherapy Reverses Immune Response to SARS-CoV-2 Vaccine in Patients with Allergic Rhinitis: A Prospective Observational Trial.变应原免疫疗法逆转过敏性鼻炎患者对SARS-CoV-2疫苗的免疫反应：一项前瞻性观察性试验。
Am J Respir Crit Care Med. 2022 Sep 15;206(6):780-783. doi: 10.1164/rccm.202203-0608LE.